We believe ITAB Shop Concept’s (ITAB’s) transformation over the past couple of years has gone largel...
Redeye embraces Devyser’s agreement with Thermo Fisher regarding its post-transplantation monitoring...
Agilyx published their FY 2022 report this morning, with USD 16.
Redeye saw sales roughly in line with our expectations in the Q1 report, as deliveries of Carbonhand...
Vitrolife enters 2023 with good progress and 9% organic growth.
Redeye thinks that the Q1 operational update from Zwipe was softer than our expectations.
Redeye judges that Ultimovacs announcing a slight delay for its phase II INITIUM readout from H1 202...
Atria reported Q1 EBIT of EUR 10.9m, 244% (EUR 7.7m) above Refinitiv consensus and 142% above our es...
Redeye updates on W5 ahead of its Q1-results (due 4 May) where expect strong growth driven by solid ...
Redeye provides an update following Nitro Games Q1 2023 report, which showed lower revenues and cost...
We expect a relatively good first quarter for ESL Shipping, due to increased q/q volumes, despite Fi...
NAV (+0.4%) up for 11th straight quarter +24% return mainly driven by 12pp narrowing of discount NAV...
Devyser har aviserat att de ingått ett exklusivt samarbetsavtal med Thermo Fischer Scientific.
I Europa förbrukas ca 60 miljoner ton plast årligen, men där endast 4 % är återvunnet och resten för...
Redeye endorses today’s news that Xbrane has submitted its BLA to the FDA for its biosimilar candida...
Redeye provides an initial comment on Carasent's shift in focus towards the Swedish market, citing "...
XVIVO has performed well in 2023. Both the organic growth (35%) and the improved gross margins (74.
Agilyx has announced this morning that they have entered into a strategic collaboration with BioBTX,...
Inför Q1-rapporten räknar Analysguiden med minskad omsättning och pressad lönsamhet.
Redeye is positive that Bioservo has registered Carbonhand as a medical-technical product according ...
